Radiopharm Theranostics Limited (AU:RAD) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Radiopharm Theranostics has announced promising results from a study on their imaging agent 68Ga-RAD 301, indicating its potential in accurately visualizing pancreatic cancer tumors and metastases. The study, which involved 44 patients, highlighted the agent’s safety and effectiveness, paving the way for its use in improving pancreatic cancer diagnostics. Currently, a Phase I trial is underway to further explore its capabilities.
For further insights into AU:RAD stock, check out TipRanks’ Stock Analysis page.